Oct 30, 2020 / Meeting Brief

Effects of pharmaceutical manufacturer rebates on Part D’s risk adjustment

Oct 29, 2020 / Comment Letters

MedPAC comment on CMS’s proposed rule on Medicare Coverage of Innovative Technology and definition of ‘reasonable and necessary’

Research Areas:

Beneficiaries and Coverage, Drugs, Devices, and Tests, Medicare Spending and Financing

Oct 06, 2020 / Transcripts

October 2020 meeting transcript

Research Areas:

Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality

Oct 02, 2020 / Presentations

The evolution of Medicare’s advanced alternative payment models

Research Areas:

Delivery System Reforms

Oct 02, 2020 / Presentations

Vertical integration and Medicare payment policy

Research Areas:

Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Private Plans

Oct 02, 2020 / Comment Letters

MedPAC comment on CMS’s proposed rule on CY 2021 revisions to payment policies under the physician fee schedule and other changes to Part B payment policies

Research Areas:

Drugs, Devices, and Tests, Medicare Spending and Financing, Physicians And Other Health Professionals, Quality

Oct 02, 2020 / Comment Letters

MedPAC comment on CMS’s proposed rule on the payment systems for hospital outpatient departments and ambulatory surgical centers for 2021

Research Areas:

Ambulatory Care Settings, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing

Oct 01, 2020 / Presentations

Future research directions in hospice payment policy

Research Areas:

Post-Acute Care

Oct 01, 2020 / Presentations

Mandated report on the skilled nursing facility value-based purchasing program: An alternative value incentive program that corrects current shortcomings

Research Areas:

Post-Acute Care, Quality

Oct 01, 2020 / Presentations

Balancing financial pressure and equity in Medicare Advantage benchmark policy

Research Areas:

Private Plans